Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.59 |
| ▸ | SYK | P43405 | 13/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CD63 | P08962 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5241034 | 0.93 | BTK (0.60) | BTKSYKAURKAPOLB | |
| SCHEMBL5273470 | 0.90 | BTK (0.57) | BTKSYKCSNK2A2FLT3AURKA | |
| SCHEMBL2216067 | 0.89 | BTK (0.76) | BTKSYKUSP2TP53MAPT | |
| SCHEMBL5237944 | 0.87 | BTK (0.60) | BTKSYKAURKAPOLB | |
| SCHEMBL5240542 | 0.87 | SYK (0.77) | BTKSYKAURKAPOLB | |
| SCHEMBL5238055 | 0.86 | BTK (0.66) | BTKSYKJAK2FLT3 | |
| SCHEMBL5276873 | 0.84 | BTK (0.57) | BTKSYKAURKAPOLB | |
| SCHEMBL5240398 | 0.84 | BTK (0.56) | BTKSYKCD63JAK2NTRK1 | |
| SCHEMBL5240818 | 0.84 | BTK (0.56) | BTKSYKCD63JAK2NTRK1 | |
| SCHEMBL5241250 | 0.83 | BTK (0.57) | BTKSYKCD63JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812442-A2 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | claimed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812442-A2 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | BTK, SYK, LCK | BTK 1/4885SYK 2/4885USP2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.